• 03.12.2018 – 09:56

  Grünenthal Gruppe

  Grünenthal closes deal with AstraZeneca for Nexium and Vimovo

  Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (EUR 811 m). "Today is an important day for Grünenthal," said Gabriel Baertschi, CEO Grünenthal. "This transaction represents a significant step towards our vision of creating a world free ...

• 30.10.2018 – 08:43

  Grünenthal Group

  Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

  Aachen (ots) - - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need [1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Grünenthal today announced that it has agreed to acquire AstraZeneca's European ...

• 11.10.2018 – 12:57

  Janssen Pharmaceutica

  Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology

  Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...

• 27.09.2018 – 11:36

  Jacobs University Bremen

  New findings on Bechterew's disease

  Autoimmune diseases are those in which our immune systems mistakenly attack our own bodies. Bechterew's disease (also known as anylosing spondylitits) is one such autoimmune disease. Now, researchers at Jacobs University Bremen have come one step closer to understanding the molecular mechanisms of this disease. Bechterew's disease is characterized by long-term painful inflammation of the joints and deformation of the ...